Thursday, November 19, 2009

Lamisil

Protected by Copyscape Plagiarism Checking Tool

Lamisil is also known by the generic name terbinafine and is available in the form of lamisil tablets or lamisil pills and lamisil cream. Lamisil generic terbinafine possess antifungal property because of which they are used to fight fungal infections on the toenail or fingernail. Lamisil functions by hindering the ability of fungi to produce chemicals known as sterols that make the main part of the membrane that is responsible for surrounding fungal cells and holding them together. As a result, it deteriorates the cell membrane.

Approved by the FDA, terbinafine tablets are prescribed to treat fungal nail infections. The cream and solution forms of terbinafine are prescribed for other fungal infections including jock itch, athlete's foot, and ringworm. The terbinafine solution helps in curing a fungal infection that produce brown, tan, or white spots on the body called tinea versicolor. 250-milligram is the terbinafine dosage that is prescribed in the form of terbinafine tablet. However, rather than producing instant results, it will take several months to obtain the complete effect of the tablets and healthy new nail grows out slowly.

Side effects of the cream and solution are rarely caused like itching, burning, dryness, peeling, rash etc. More common lamisil tablets side effects include: diarrhea, rash and indigestion. Less common lamisil side effects include: itching, abdominal pain, gas, hives, nausea, taste disturbances, vision problems, while the rare problems are fatigue, flu- symptoms, joint pain, hair loss, muscle aches, liver problems and vomiting. Changes in the lens and retina of the eye are also reported with using lamisil tablets and rarely liver damages. Terbinafine and alcohol can cause health hazards when taken together. It also causes several drug interactions with medicines like Antidepressants, Cimetidine, Cyclosporine, Rifampin etc. This drug should be avoided by breast feeding mothers and pregnant women.

No comments:

Post a Comment